Tin tức & Cập nhật

Asia’s first histotripsy 2.0 system, introduced at the Chinese University Hong Kong (CUHK) recently, will be used in clinical trials to treat liver cancer patients from early 2025. The novel focal therapy will also be evaluated in patients with early-stage breast cancer.

For new mothers who have undergone breast cancer treatment, including those who harbour the BRCA gene mutation, breastfeeding appears to be a safe and viable option, posing no increased risk of recurrence or development of new breast cancers, according to new research.

A study suggests that in choosing CDK4/6 inhibitors (palbociclib and abemaciclib) for patients with hormone receptor-positive, HER2-negative metastatic/recurrent breast cancer, considerations must be made based on the tolerability and manageability of adverse events (AEs).